

AMENDMENTS TO THE SPECIFICATION

Kindly amend the specification as follows.

Please replace the paragraph beginning on page 12, line 22, with the following amended paragraph:

The oligopeptide or polypeptide of the invention can also comprise an amino acid sequence which is a constituent sequence of SEQ ID NO: 12 containing at least 5 consecutive amino acids of SEQ ID NO: 12, with the constituent sequence at least including one of the positions 72 73, 78, 112, 122 and 139 of SEQ ID NO: 12. These amino acid positions correspond to positions 115, 120, 154, 164 and 181 of the S antigen of HBV. The constituent sequence preferably comprises at least 6, more preferably at least 7, most preferably at least 8, consecutive amino acids of the amino sequence shown in SEQ ID NO: 12. In other embodiments, the constituent sequence comprises at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95 or at least 100 consecutive amino acids of the amino acid sequence shown in SEQ ID NO: 12.

Also, please replace the paragraph beginning on page 13, line 5, with the following amended paragraph:

The constituent sequence preferably includes two, three, four, or all five, of the positions 72 73, 78, 112, 122 and 139 of SEQ ID NO: 12.